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Summary 
Induction and maintenance of a state of T  cell unresponsiveness to specific alloantigen would 
have significant implications for human organ transplantation. Using human histocompatibility 
leukocyte antigen DR7-specific helper T  cell clones, we demonstrate that blockade of the B7 
family of costimulatory molecules is sufficient to induce alloantigen-specific T cell clonal anergy. 
Anergized cells do not respond to alloantigen and a variety of costimulatory molecules, including 
B7-1,  B7-2,  intercellular adhesion molecule-1 (ICAM-1),  and lymphocyte function-associated 
molecule (LFA)-3. However, after culture in exogenous interleukin (IL)-2 for at least 7 d, anergized 
cells can respond to alloantigen in the presence of LFA-3.  LFA-3 costimulation subsequently 
restores responsiveness to alloantigen in the presence of previously insufficient costimulatory signals. 
Expression of CD2R epitope is downregulated on anergic cells and is restored after 7 d of IL-2 
culture. The loss of the CD2R is temporally associated  with the inability of anergized cells to 
respond to LFA-3. These results suggest that in addition to blockade of B7 family members, 
inhibition of CD2 and, potentially, other costimulatory pathways that might reverse anergy will 
be necessary to maintain prolonged alloantigen-specific tolerance. 
S 
uccessful human allogeneic bone marrow and organ trans- 
plantation is presently dependent on the chronic adminis- 
tration of toxic nonspecific immunosuppressive agents. How- 
ever, if long-lasting and potentially irreversible tolerance to 
alloantigen could be induced, then the associated attendant 
clinical toxicities might be ameliorated and the eligible donor 
pool would be increased. Approaches to achieve this objec- 
tive would be to specifically inhibit the expansion of alloreactive 
T  cells and, more importantly, devise strategies to induce 
anergy to donor-specific alloantigens. 
For clonal expansion and effector function, alloreactive T 
cells require two signals (1). Signal I is both antigen specific 
and MHC restricted and is delivered to the TCR complex. 
Signal 2, termed costimulation, is provided by one or more 
accessory molecules expressed on alloantigen-presenting cells 
(allo-APCs) a. Costimulatory signals, in contrast to signal 1, 
are neither antigen specific nor MHC restricted, yet they are 
essential to induce maximal T cell proliferation, cytokine secre- 
tion, and induction of effector function (2-10). Engagement 
of the TCR by aUoantigen without requisite costimulation 
fails to induce an immune response, but rather results in a 
state of antigen-specific unresponsiveness, termed anergy (11, 
12). Although a large number of experimental systems have 
t Abbreviations used in this paper: allo-APC, alloautigen-presenting  cell; 
ICAM-1, intercellular  adhesion  molecule  1; LBL, lymphoblastoid  cell  line. 
been developed to examine the mechanism(s) of anergy in 
both murine and human systems (12-16), little is known about 
which costimulatory molecules are involved in the induction, 
maintenance, and reversal  of this state. 
Of the numerous costimulatory molecules expressed on 
allo-APCs, preliminary studies demonstrated that B7-mediated 
costimulation appears to be critical to prevent the induction 
of anergy (17-22). Two members of the B7 family of costimula- 
tory molecules, B7-1 and B7-2, have been molecularly cloned 
and are expressed on activated B lymphocytes and a variety 
of APCs (23-30). CD28, which serves as a major functional 
B7 family receptor, is constitutively expressed on resting T 
cells and is upregulated after activation (31). After signal 1 
via the TCR, ligation of CD28 by either B7-1 or B7-2 results 
in IL-2 secretion and T  cell proliferation (6,  7,  32,  33). T 
cells also express a second inducible receptor for the B7 family 
termed CTLA4 (34), which serves as the high affinity receptor 
for B7  (35).  An immunoglobulin tailed fusion protein of 
CTLA4 (CTLA4-Ig) has proven to be the most effective re- 
agent to inhibit B7 family member-mediated costimulatory 
function (19,  21, 32,  35). Recently, the importance of B7- 
mediated costimulation  in  the prevention  of anergy was 
demonstrated when the consequences of B7-1- and intercel- 
lular adhesion molecule-1 (ICAM-1)-mediated costimulation 
were directly compared  (36).  Whereas  B7-1  or  ICAM-1 
costimulatory molecules were equally potent in their ability 
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tive CD4 + T  cells, only B7-1 costimulation was accompa- 
nied by significant IL-2 accumulation, thereby preventing the 
induction of anergy. In contrast, ICAM-l-mediated costimu- 
lation did not induce detectable IL-2 accumulation and did 
not  prevent  the  induction  of human  alloantigen-specific 
anergy. 
Although blockade of the B7 costimulatory family appears 
to be critical for the induction of anergy, a major concern 
is whether other costimulatory molecules expressed on allo- 
APCs might reverse the established state of anergy. We and 
others have observed that anergized T  cells can proliferate 
in response to exogenous IL-2 (12,  18, 36,  37).  Moreover, 
antigen-specific  T  cell  clonal  anergy  can  be  reversed  by 
prolonged culture of anergized cells in IL-2 followed by pre- 
sentation of that same antigen by professional APC (37, 38). 
The capacity of endogenous IL-2 to reverse  anergy would 
present a significant obstacle to implementing the induction 
of alloantigen-specific anergy as a clinical strategy. Therefore, 
we sought  to determine how addition  of exogenous IL-2 
would reverse the state of human alloantigen-specific anergy 
in vitro, and if so, which costimulatory molecules are involved 
in this response. 
Materials  and Methods 
Human T  Cell Clones.  HLA-DR7 alloantigen-specific T cell 
clones were generated by use of standard methodology (39). Briefly, 
PBMCs from an HLA-DR7/DR1/DR8-negative individual were 
stimulated with an HLA-DR7 homozygote  EBV-transformed  lym- 
phoblastoid cell line (LBbDR7), which strongly expresses MHC 
class II,  B7-1, B7-2, ICAM-1,  and LFA-3 molecules, in  1:1 re- 
sponder/stimulator  ratio at a concentration of 106 cells/ml. After 
three repetitive stimulations, alloactivated T cells were isolated by 
Percoll gradient  in the 40-50% fraction and cloned by limiting 
dilution  (0.3 cells/well)  in  96-well flat-bottom  plates (Nunc, 
Roskilde, Denmark). Clones were expanded in 24-well plates with 
addition of flesh IL-2 (50 U/m1) (Collaborative Biomedical Prod- 
ucts, Bedford, MA) every 5 d and restimulation  with LBL-DR7 
stimulators every 10 d. Before each experiment, T cell clones were 
rested for 10 d to 2 wk after restimulation.  Before use, cells were 
resuspended in complete culture medium consisting of RPMI 1640 
with 10% heat-inactivated FCS, 2 mM glutamine, 1 mM sodium 
pyruvate, penicillin (100 U/m1), streptomycin sulfate (100 #g/m1) 
and gentamicin sulfate (5 #g/ml) and cultured overnight without 
any stimulus or IL-2. 
Monoclonal Antibodies and Fusion Proteins.  mAbs were used as 
purified Ig unless indicated otherwise:  anti-B7 (133): IgM (23); 
BB-I: IgM (40) (Dr. E. Clark, University of Washington, Seattle, 
WA); anti-MHC class II: 9-49, IgG2a (41) (Dr. R. Todd, Univer- 
sity of  Michigan, Ann Arbor, MI); anti-LFA-la: TS1/22, IgG1 (42) 
and anti-LFA-3: TS2/9, IgG1 (43) (Dr. T. Springer, Center for Blood 
Research, Boston, MA); anti-CD24 (BA-1,l:100  ascites) (44), anti- 
CD40 (JRG 12): IgG1, anti-CD72 (J3-109, BU-40, 1:100 ascites) 
(45); anti-CD2 (Tl1.1, Tll.2, Tll.3): IgG1 (46). Construction of 
human CTLA4-Ig (18) and control fusion protein (control-Ig) (36) 
was previously described. All (purified) mAbs and fusion proteins 
were used at  10 #g/ml. 
NIH 3T3 and COS Transfected Cells.  Alloantigen and/or co- 
stimulatory  molecules were presented by use of NIH-3T3 stable 
transfectants (t-) that had been named artificial allo-APCs. The prep- 
aration of these allo-APCs has been previously  described (36). COS 
cells were transfected with cDNAs encoding either HLA-DRot and 
DR73 (DRBI*0701) chains (COS-DR7), B7-1 and B7-2 (COS- 
B7-1/B7-2),  HLA-DRot  and  DR73,  B7-1 and  B7-2 (COS- 
DR7/BT-1/B7-2), LFA-3 (COS-LFA-3), HLA-DRot and DR73 
and LFA-3 (COS-DR7/LFA-3),  HLA-DRa and DR73, LFA-3, 
B7-1 and B7-2 (COS-DR7/LFA-3/B7-1/B7-2),  or pCDNAI vector 
alone (COS-mock). The expression of DR7 and LFA-3 were as- 
sessed by use of 9-49 (41) and TS2/9 (43) mAbs, respectively, fol- 
lowed by FITC-conjugated goat anti-mouse Ig; the expression of 
B7-1 and B7-2 was assessed by use of biotinylated CTLA4-Ig, fol- 
lowed by phycoerythrin-conjugated streptavidin. The coexpression 
of LFA-3 and DR7 was assessed by use of TS2/9 (43) followed 
by FITC-labeled goat anti-mouse Ig and phycoerythrin-conjugated 
9-49 (41); it was detectable in 72% of the untransfected cells (data 
not shown). The coexpression  of DR7 and B7-1/B7-2 was assessed 
by use of FITC-conjugated 9-49 (41) and biotinylated CTLA4-1g 
(18) followed by phycoerythrin-conjugated streptavidin; it was de- 
tectable in 50% of the transfected cells (data not shown). 
Primary and Secondary Stimulation.  Alloantigen-specific T cell 
clones were incubated in a primary culture  with either t-DR7, 
t-DR7/B7-1, LBL-DR7, LBL-DR7 +  anti-B7-1 (133) mAb (23), 
or LBL-DR7  +  CTLA4-Ig fusion protein  (18) (which  blocks 
costimulation by B7-1 and B7-2). TC-1 and allo-APCs were cul- 
tured at the optimal 1:1 ratio (Boussiotis, V. A., unpublished  results). 
After 72 h of  primary culture, TC-1 cells were isolated from artificial 
allo-APCs by Percoll gradient centrifugation and from LBL-DR7 
by Ficoll separation, washed extensively, and cultured in media 
without  I1,-2 for  24  h.  Each population  was  subsequently 
rechallenged with a secondary stimulus: (a) each one of the allo- 
APCs (t-DRT,  t-DR7/B7, t-DRT/ICAM-1);  (b) LBL-DR7; and 
(c) IL-2 (100 IU/ml). The secondary stimulation with artificial allo- 
APCs or LBL-DR7 was also performed at  1:1 ratio (2.5  x  104 
cells/well). Samples were cultured in triplicate in flat-bottom 96- 
well culture plates at 37~  for 72 h in 5% CO2. Artificial allo- 
APCs and LBL-DR7 cells were treated with 20 #g/ml mitomy- 
cin-C (Sigma Chemical Co., St. Louis, MO) at 37~  for 2 h and 
then washed extensively before use. For some experiments, LBL- 
DR7 cells were irradiated at 9,600 rads or fixed with paraformalde- 
hyde according to a previously described protocol (7). 
IL2 Culture and Reversal of  Anergy.  T cell clones were first aner- 
gized by primary stimulation with t-DR7 and then cultured in 
IL-2 for 3 to 21 d. At several time intervals of IL-2 culture, T cell 
clones were rechallenged in a secondary stimulation as above, with 
either (a) allo-APCs (t-DR7, t-DR7/B7, t-DR7/ICAM-1);  (b) LBL- 
DR7 alone or in the presence of each one of the following mAbs 
or fusion proteins: anti-DR, anti-LFA-1, anti-LFA-3,  anti-B7-1 (133), 
BB-1, CTLA4-Ig,  anti-CD24,  anti-CD40,  anti-CD72;  or  (c) 
COS-mock, COS-DR7, COS-B7-1/B7-2, COS-LFA-3, COS-DRT/ 
B7-1/B7-2, COS-DR7/LFA-3,  COS-DR7/LFA-3/B7-1/BT-2.  To 
determine whether alloantigen-specific  responsiveness  can be fully 
restored after IL-2 culture and examine the role of several  costimula- 
tory pathways in the reversal of anergy, T cell clones cells were 
anergized by primary culture with t-DR7, maintained in IL-2  (100 
IU/ml) for 7 d, and rechallenged in a secondary stimulation with 
LBL-DR7, COS/DR7/LFA-3,  or COS/DR7/B7-1/B7-2.  For these 
experiments, secondary  stimulation was performed in 24-well  plates; 
TC-1 cells were isolated from LBL-DR7 by Ficoll separation and 
from COS transfectants by Percoll  gradient centrifugation and sub- 
sequently rechallenged with each one of the following stimuli: (a) 
allo-APCs (t-DR7, t-DR7/B7, t-DR7/ICAM-1), (b) LBL-DR7, 
or (c) IL-2 (100 IU/ml). Stimulation with artificial allo-APCs or 
LBL-DR7 was  performed  in  1:1  ratio  (2.5  x  104 cells/well). 
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Thymidine Incorporation.  Thymidine incorporation was used as 
an index of mitogenic activity. During the last 16 h of a 72-h cul- 
ture period, cells were incubated with 1/zCi of [methyl-3H]thymi  - 
dine (DuPont, Boston, MA). The cells were harvested onto filters, 
and the radioactivity on the dried filters was measured in a fl-plate 
liquid scintillation counter (Pharmacia LKB, Uppsala, Sweden). 
11_,2 Assay.  II,-2  accumulation was measured by ELISA (Bio- 
source, Camarillo, CA) in supernatants harvested 24 h after the 
initiation  of the cultures. 
Results 
Absence of  Costimulation by B7 Family Members Induces  Human 
Alloantigen-specific ClonalAnergy.  Artificial allo-APCs were 
made by transfection of HLA-DR7 alone (t-DR7) or with 
B7-1 (t-DR7/B7-1) or ICAM-1 (t-DR7/ICAM-1) in NIH- 
3T3 cells (36). t-DR7/B7-1, t-DR7/ICAM-1,  and a HLA- 
DR7 homozygous lymphoblastoid cell line (LBL-DR7) in- 
duced equally potent T  cell clonal proliferation (data not 
shown). T cell clonal proliferation was alloantigen mediated 
since no response was observed in the absence of HLA-DR7 
(transfectants expressing only B7-1  or ICAM-1  alone)  or 
blocking DR on t-DR7/B7-1, t-DR7/ICAM-1, or LBL-DP,,7 
stimulators with anti-DR mAb (data not shown). All studies 
described here were conducted simultaneously with two helper 
T  cell clones  (TC-1  and  TC-2)  (CD4 +  CDS-  CD28+). 
Since  the results with both clones were consistently com- 
parable,  only results with TC-1 are presented. 
To determine whether TCR signaling in the absence of 
costimulation induced by members of the B7 family was 
sufficient to induce T  cell clonal anergy, TC-1 clones were 
cocultured for 72 h with either t-DR7, t-DR7/B7, or LBL- 
DR7 cells  alone or in  the presence of anti-B7-1  mAb  or 
CTLA4-Ig.  After primary culture,  TC-1  cells  were  then 
rechallenged with either artificial allo-APCs, LBL-DR7 cells, 
or IL-2. Primary culture with t-DR7 resulted in an anergic 
response on rechallenge (absence of [3H]thymidine incorpo- 
ration and IL-2 accumulation) (Fig.  1 A). In contrast, pri- 
mary culture with either t-DR7/B7-1 or LBL-DR7 resulted 
in  a  significant  secondary proliferative response and  IL-2 
accumulation (Fig.  1, B  and C).  Addition of anti-B7-1 to 
LBL-DR7 cells in the primary culture resulted in reduced 
proliferation and IL-2 accumulation but did not induce un- 
responsiveness on rechallenge (Fig.  1 D). However, primary 
culture with LBL-DR7 in the presence of CTLA4-Ig resulted 
in anergy (Fig. 1 E). In all instances, anergized and nonaner- 
gized cells responded equally well to exogenous IL-2. These 
results  demonstrate  that  blockade  of  the  B7  family  of 
costimulatory molecules is necessary to induce anergy. Since 
all other costimulatory molecules expressed on LBL-DR7 cells 
that are not blocked by CTLA4-Ig did not prevent the in- 
duction of anergy, these results also  suggest that blockade 
of the B7 family is sufficient to induce anergy. Moreover, 
after the induction of anergy, neither B7 family members nor 
other non-B7 costimulatory molecules expressed on LBL-DR7 
cells appear to be capable of reversing this state. 
Restoration of AUoantigen-specific Responsiveness After Cul- 
A 
C 
D 
Primary  Rechallenge 
Stimulus 
t-DR7 
t-DR7 / B7-1 
LBL-DR7 
LBL-DR7 
+ 
o.87-1 
LBL-DR7 
+ 
CTLA4-1g 
t-DR7 
t-DR7 / B7-1 
t-DR7 / ICAM-1 
LBL-DR7 
IL-2 
t-DR7 
t-DR71 B7-1 
t-DR7  / ICAM-1 
LBL-DR7 
IL-2 
t-OR7 
t-DR7  f 87q 
t-DR71 ]CAM4 
LBL-DR7 
IL-2 
D 
H 
I  t  t 
m 
W//////////////////////////A'- 
~///////////////////////'//////'/////~ 
t-DR7  m 
t-DR7 / 87-1 
t-DR7 / ICAM-1 
L  B  L- D  R  7  z/////////'/////A--~ 
IL-2 
I  I  I 
t-DR7 / 87-I  El 
t-DR71 ICAM-I  ~I 
LBL-DR7  ~I 
IL-2  ____.__]--I 
I 
[ 3H]-Thymidine  Incorp. (cpm x 10 -3 ) 
1I.-2 
(pg/ml 
< 20 
<20 
<20 
< 20 
ND 
24 
680 
24 
57O 
NO 
25 
578 
26 
490 
ND 
<20 
128 
< 20 
98 
ND 
< 20 
< 20 
< 20 
< 20 
ND 
Figure 1.  TCR signaling in the absence  of costimulation  by B7 family 
members induces aUoantigen-specific  clonal anergy. Alloantigen-specific 
TC-1 clone  was primarily  cultured  with either  t-DR7, t-DR7/B7-1, LBL- 
DR7, LBL-DR7 + anti-B7-1  (133)  mAb, or LBL-DR7 + CTLA4-1g  fu- 
sion protein. After 72 h of primary  culture, TC-1 cells were  isolated  from 
artificial allo-APCs by Percoll  gradient and from  LBL-DR7  by Ficoll  sepa- 
ration, washed extensively,  and cultured in media without IL-2  for 24 h. 
Each population  was subsequently  restimulated  with a secondary  stimulus 
as shown. IL-2  concentration  was assessed in supernatants of 24 h of cul- 
ture, and thymidine incorporation  was measured for the last 16 h of a 
72-h culture  period. Results are representative  of seven  experiments.  Solid 
bars represent response  of TC-1 cells to artificial allo-APCs, stripped  bars 
represent response  to LBL-DR7,  and open bars represent  response to exog- 
enous recombinant human IL-2. 
ture in IL-2.  TC-1 cells were anergized by primary culture 
with t-DR7 and then cultured in IL-2 for 3-21 d to deter- 
mine whether IL-2 could restore responsiveness to specific 
alloantigen. At any time up to 21 d  after IL-2 incubation, 
rechallenge in the secondary culture with t-DR7, t-DR7/B7-1, 
or t-DR7/ICAM-1  did not induce response (Fig.  2 A)  at 
a wide range of stimulator/responder ratios (data not shown). 
In contrast, after at least 7 d of IL-2 culture, rechallenge with 
LBL-DR7 induced a proliferative response (Fig.  2, A  and 
B), which was associated with significant accumulation of 
IL-2 (Fig.  2 B). Response induced by LBL-DR7 cells was 
alloantigen specific since it was inhibited by anti-DR mAb, 
and two other DR homozygous LBLs (LBL-DR1 and LBL- 
DR8) did not induce proliferation or IL-2 accumulation (Fig. 
2 B). After prolonged IL-2 culture, alloantigen-specific re- 
1667  Boussiotis  et al. A 
5o 
Media 
LBL-DR7 
LBL-DR7 + 
anti-DR 
LBL-DR1 
LBL-DR8 
~,// 
LBL-DR7 
t-DR7 
t-DR7 / B7-1 
t-DR7 / ICAM-1 
10  20  30 
Days Following Culture in IL-2 
[L-2 
B  ( pg/m[ ) 
I 
I 
1  I  I 
20  40  60  80 
[3 H ]-Thymidine Incorp.  ( cpm x 10 3) 
38 
480 
42 
38 
36 
Figure  2.  (A) After prolonged culture in IL-2,  LBL-DR7  but not artificial 
allo-APCs can restore responsiveness of anergized TC-1 cells to specific 
alloantigen. TC-1 cells were first anergized by primary stimulation with 
t-DR7, and then cultured in IL-2 for 7 to 21 d. At the indicated time 
intervals of II,-2 culture, these TC-1 cells were rechallenged with equal 
numbers of each type of artificial allo-APCs or LBL-DR7 as stimulators. 
Proliferation was measured as in Fig. 1. Results are representative of five 
experiments. (B) Reversal of anergy by LBLDR7 stimulators after IL-2 
culture is alloantigen specific. After induction of anergy with t-DR7 allo- 
APCs followed by culture in IL-2 for 7 d, TC-1 cells were rechallenged 
with either LBL-DR7, LBL-DR7  + anti-DR mAb, LBL-DR1, or LBL-DR8. 
Proliferation and IL2 accumulation were measured as in Fig. 1. Results 
are representative of three experiments. 
sponsiveness can be restored, but neither B7-1 nor ICAM-1 
appear to be  sufficient  to provide costimulation. 
The  capacity  of LBL-DR7  ceils  to  restore  alloantigen- 
specific response was not mediated by a secreted soluble factor 
since rechallenge with t-DR7/B7 or t-DR7/ICAM-1 in the 
presence of LBL-DR7 culture supernatant did not restore re- 
sponsiveness (data not shown). In contrast, paraformaldehyde- 
fixed LBL-DR7 induced the identical proliferative response 
as mitomycin C-treated  or irradiated  LBL-DR7 cells,  sug- 
gesting that a cell surface molecule and not a soluble factor 
is involved in reversal of anergy (data not shown). Taken to- 
gether, these results suggest that a paraformaldehyde-resistant 
cell surface molecule that is neither B7-1 nor ICAM-1 costimu- 
lates  with  alloantigen  to  restore  responsiveness  after  IL-2 
culture. 
To determine whether a known costimulatory molecule(s) 
is responsible  for the  restoration  of alloantigen-specific  re- 
sponsiveness by LBL-DR7  stimulators,  blocking  mAbs  or 
fusion proteins directed against a variety of costimulatory mol- 
ecules expressed on APCs were used.  Only anti-DR,  anti- 
LFA-1, and anti-LFA-3 mAbs inhibited  the proliferative re- 
sponse  (Fig.  3).  Neither  B7  family  members  nor  other 
costimulatory molecules, including CD24, CD40, and CD72, 
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Figure  3.  LFA-3, but  not 
other known costimulatory mol- 
ecules, are involved  in the reversal 
of  alloantigen-specific  clonal 
anergy. After  anergy induction 
with t-DR7 allo-APCs followed 
by culture in II.-2 for at least 7 d, 
TC-1 cells were rechallenged with 
LBL-DR7 either alone or in the 
presence of each of the following 
mAbs or fusion proteins: anti- 
DR, anti-LFA-1, anti-LFA-3, anti- 
B7-1  (133), BB-1, CLTA4-Ig, 
anti-CD24, anti-CD40, and anti- 
CD72. Proliferation  was measured 
as in Fig. 1. Results are represen- 
tative of four experiments. 
appear to be important for the reversal of anergy. These results 
are consistent  with  the  hypothesis  that  LFA-3  and  alloan- 
tigen are the molecules responsible for the observed reversal 
of anergy. We doubt that LFA-1 and alloantigen are involved 
in the reversal of anergy,  since t-DR7/ICAM-1  did not re- 
store proliferation of anergized cells after culture with IL-2 
(Fig. 2 A). However, we cannot exclude the possibility that 
other LFA-1 ligands (i.e., ICAM-2 or ICAM-3) also might 
contribute  to  the reversal of anergy. 
It has been shown that LFA-3 can provide costimulation 
to antigen-specific T  cell activation (5, 47,  48).  To examine 
whether LFA-3 costimulation is also sufficient to reverse the 
state of established  alloantigen-specific clonal anergy,  COS 
transfectants expressing DR7 alone (COS-DR7),  costimula- 
tory molecules alone (COS-B7-1/B7-2  or COS-LFA-3),  or 
DR7 in combination with one or more of these costimula- 
tory molecules (COS-DR7/B7-1/B7-2,  COS-DR7/LFA-3, 
COS-DR7/LFA-3/B7-1/B7-2) were made. TC-1 cells were 
anergized with t-DR7  allo-APCs, cultured  in IL-2 for 7 d, 
and then rechallenged with the different populations of COS 
transfectants.  As shown in Fig.  4 A, challenge with COS- 
DR7,  COS-B7-1/B7-2,  COS-LFA-3,  and  COS-DR7/B7- 
1/B7-2  did not  induce  proliferation  or IL-2 accumulation. 
In contrast, transfectants coexpressing DR7 and LFA-3 (COS- 
DR7/LFA-3  and  COS-DR7/LFA-3/B7-1/B7-2)  induced 
equivalent levels of proliferation and IL-2 accumulation,  in- 
dicating that after prolonged IL-2 culture, responsiveness to 
alloantigen can be restored in the presence of LFA-3 costimu- 
lation.  Attempts  to culture  anergized  TC-1  cells in media 
without IL-2, in order to determine whether exogenous IL-2 
is necessary before rechallenge for the reversal of anergy, were 
unsuccessful since all our alloantigen-specific clones were IL-2 
dependent  and  so underwent  apoptosis  after IL-2 depriva- 
tion  for longer  than  72  h  (data  not  shown). 
Reversal of  Anergy by Specific  Alloantigen and LFA-3 Costimu- 
lation.  We then sought to determine whether LFA-3 costimu- 
lation had reversed anergy and fully restored alloantigen-specific 
responsiveness of anergized cells. TC-1 cells were anergized 
by primary culture with  t-DR7,  cultured  in  IL-2 for 7  d, 
and co-cuhured with either LBL-DR7,  COS-DR7/LFA-3, 
or COS-DR7/B7-1/B7-2 for an additional 3 d, as above. These 
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Figure  4.  (.4) Alloantigen-specific  anergy can be partially reversed by 
artificial APCs expressing alloantigen  and LFA-3. After anergy induction 
with t-DR.7  allo-APCs  followed by culture in recombinant  human I1,2, 
TC-1 cells were rechallenged  with the indicated  types of COS transfec- 
tants. Proliferation and II,2 accumulation were measured as in Fig. 1. Results 
are representative of three  experiments  with COS-DR7/LFA-3,  COS- 
DR7/B7-1/B7-2, and COS-mock, and two experiments with COS-DR.7, 
COS-LFA-3,  COS-B7-1/B7-2,  and COS-DR7/LFA-3/B7-1/B7-2 trans- 
fectants. (B) Alloantigen and LFA-3 restore the capacity of anergized cells 
to respond to subsequent rechallenge with specific alloantigen in the pres- 
ence of previously  insufficient  costimulatory molecules.  After anergy in- 
duction with t-DR7 allo-APCs  followed by culture  in I1,2,  TC-1 cells 
were rechallenged  with either  LBL-DR7,  COS-DR7/LFA-3,  or COS- 
DP,.7/B7-1/B7-2 for 72 h. Subsequently,  they were isolated  from LB1, 
DR7 by Ficoll separation and from COS transfectants by Percoll gradient 
and rechallenged with the shown stimuli. Proliferation and I1,2 accumu- 
lation were measured as in Fig. 1. Results are representative of four experi- 
ments when rechallenge  was done with LBL-DR7 stimulators  and two 
experiments when rechallenge was done with COS transfectant stimulators. 
cells were then rechallenged  with either t-DR7, t-DR7/B7-1, 
t-DR.7/ICAM-1,  or LBL-DR7. After sequential culture with 
IL-2 and LBL-DR7  or COS-DR7/LFA-3,  previously aner- 
gized  TC-1  cells  proliferated  in  response  to  t-DR7/B7-1, 
t-DR7/ICAM-1,  and LBL-DR7  (Fig. 4 B, top and middle). 
In contrast, when COS-DR7/B7-1/B7-2  were used instead 
of LBL-DR7 after IL-2 culture, no response on rechallenge 
was  seen  (Fig.  4 B,  bottom). In  all  instances,  TC-1  cells 
proliferate  equally to exogenous  IL-2.  Culture in  IL-2 for 
at least 7 d followed by presentation of alloantigen  and costimu- 
lation with LFA-3 is sufficient to reverse alloantigen-specific 
anergy and restore responsiveness to alloantigen in the pres- 
ence  of previously insufficient  costimulatory  signals. 
Phenotypic and Functional Characterization of the CD2 Epi- 
topes During the  Induction, Maintenance, and  Reversal of 
Anergy.  LFA-3 mediates activation of T  cells via the CD2 
molecule (5, 47-50),  and distinct functional CD2 epitopes 
regulate  this  alternative  pathway  of T  cell  activation  (46, 
51-53).  Since anergized TC-1 cells did not respond to LBL- 
DR7 immediately after the induction of anergy with t-DR7 
(Fig. 1) but did respond to LBL-DR7 or COS-DR7/LFA-3 
after 7 d of IL-2 culture (Figs. 2 A  and 4 A), we attempted 
to determine whether induction and reversal of anergy cor- 
related with the expression of distinct epitopes of the CD2 
molecule.  As shown in Fig.  5, TC-1 clones expressed CD2 
(Tl1.1  and Tll.2),  and CD2R  (Tll.3)  epitopes.  After  in- 
duction of anergy with t-DR7, TC-1 cells still expressed Tl1.1 
and Tll.2 but CD2R. (Tll.3) was no longer detectable. The 
Tll.3  epitope was reexpressed after  7 d of culture in IL-2, 
precisely when these cells regained responsiveness to alloan- 
tigen  and  LFA-3  costimulation.  Moreover,  although 
nonanergic TC-1 cells proliferated to the mitogenic combi- 
nation of Tll.3  with  either  Tl1.1  or Tll.2  mAbs  (Fig.  6 
A), anergic cells did not (Fig. 6 B). After 7 d of culture with 
IL-2 and accompanying  the reappearance  of the Tll.3  epi- 
tope,  anergic  T  cells  regained  responsiveness  to mitogenic 
combinations of anti-CD2 mAbs (Fig.  6 C).  These results 
suggest that the inability of anergized TC-1 cells to respond 
to LBL-DR7 appears to be associated with the downregula- 
tion of the CD2R epitope. Moreover, the recovery of LFA-3 
responsiveness after 7 d of IL-2 culture coincided with the 
reexpression  of Tll.3. 
We have demonstrated previously that although ICAM-1 
is  as potent  as B7-1  costimulation  in its ability  to induce 
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Figure  5.  Expression  of CD2R (Tll.3)  epitope  of CD2 molecule is 
downregulated  during anergy induction and restored after 11,2 culture. 
TC-1 cells before and after induction of anergy and after culture with 11,2 
for 7 d were stained with antibodies  for the Tl1.1, Tll.2, or Tll.3 epi- 
topes of the CD2 molecule or the appropriate isotype-matched  controls 
and were analyzed by flow cytometric  analysis (Epics Elite Flow cytom- 
eter; Coulter Corp.,  Hialeah,  FL). Shaded peak represents staining with 
isotype-matched  mAb, and unshaded peak represents staining with mAbs 
for either Tl1.1, Tll.2, or Tll.3 epitopes, as indicated. Data are represen- 
tative of three  experiments. 
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Unstimulated  and  anergic  TC-1  cells  after  IL-2 culture 
proliferate to the mitogenic combination of Tll mAbs but anergic cells 
do not. TC-1 cells before stimulation, after anergization with t-DR7 ado- 
APCs, or after anergization and II+-2 culture were stimulated with mito- 
genic combinations of Tll mAbs as shown. Proliferation and I1+-2  accumu- 
lation were measured as in Fig.  1. Results are representative of three ex- 
periments. 
alloantigen-specific  proliferative response by unprimed CD4 + 
human T  cells (36) and T  cell clones  (Boussiotis,  V.  A., 
unpublished results), it cannot prevent the induction of allo- 
antigen-specific anergy. To determine whether the absence 
of CD2P, was related directly to the induction of anergy or 
simply reflected lack of T  cell proliferation,  we examined 
whether anergization with t-DR7/ICAM-1 allo-APCs was 
also accompanied by downregulation of CD2R expression. 
As was observed after anergization with t-DR7, CD2R was 
lost by 24 h and was still absent at 5 d of culture (data not 
shown) despite the fact that these cells were proliferating. 
These data  suggest  that  the observed  downregulation of 
CD2P, is associated with the induction of anergy. 
Although Involved  in the Reversal of  Anergy, LFA-3 Costimu- 
lation During Primary Culture Does Not Prevent the Induction 
of  Anergy.  In light of the evidence that antigen-specific  LFA- 
3-mediated costimulation appeared  to be critical for the reversal 
of anergy, we sought to determine whether LFA-3-medi- 
ated costimulation during primary stimulation is involved 
in the prevention of anergy. LBL-DR7 strongly express both 
alloantigen  and LFA-3, and TC-1 cells express all three epi- 
topes of the CD2 molecule. However, LFA-3 did not appear 
to be able to prevent the induction of anergy since inhibition 
of B7-mediated costimulation by CTLA4-Ig during primary 
stimulation was sufficient to induce anergy (Fig. 1 E). Similar 
to our previous results with anti-ICAM-1  mAb, anti-LFA-1 
and anti-LFA-3 mAbs significantly inhibited the capacity of 
LBL-DR7 cells to induce proliferation  and IL-2 accumula- 
tion during primary stimulation (Fig. 7 A). However, sec- 
ondary stimulation with t-DR7/B7-1 or LBL-DR7 induced 
proliferation  and IL-2  accumulation,  whereas  t-DR7 and 
t-DR7/ICAM-1 induced proliferation  without significant  IL-2 
accumulation (Fig. 7, B and C). These results show that ad- 
dition of anti-LFA-1 or anti-LFA-3 during primary stimula- 
tion did not result in antigen-specific anergy on secondary 
stimulation. Moreover, these results suggest that ICAM-1, 
LFA-1, and LFA-3 largely serve adhesive functions  during 
primary stimulation and that blockade of these pathways 
completely inhibits  recognition of antigen.  Therefore,  on 
rechallenge, alloreactive T cells appear to respond as if they 
were mounting a primary response to alloantigen. 
Discussion 
[n this report, we demonstrate that alloantigen presenta- 
tion without costimulation provided by B7 family members 
is suffident to induce human alloantigen-specific  clonal anergy. 
Once induced, anergy cannot be reversed by alloantigen and 
a variety of costimu|atory molecules expressed on LBL-DR7, 
including B7-1, B7-2, ICAM-1, and LFA-3. After prolonged 
culture in IL-2, anergized cells cannot proliferate or secrete 
cytokines in response to B7-1, B7-2, or ICAM-1 costimula- 
tion. However, under these conditions,  anergized cells can 
proliferate and secrete IL-2 in response to aUoantigen and 
LFA-3. Alloantigen and LFA-3 costimulation subsequently 
fully restores alloantigen-specific responsiveness. Induction 
of anergy is temporally related to the downregulation of the 
LFA-3 counterreceptor epitope CD2R, whereas the capacity 
of alloantigen  and LFA-3 to reverse anergy coincides with 
the reappearance of this epitope. Therefore,  the expression 
of CD2R appears to play a critical role in the induction, main- 
tenance, and reversal of human alloantigen-specific anergy. 
Based on these data, we can now postulate which signaling 
pathways appear to be defective during the induction, main- 
tenance, and reversal of aUoantigen-specific anergy. As sum- 
marized in Table 1, alloreactive T cell clones express compe- 
tent TCR complex, CD28, IL-2 receptor, and CD2. These 
A 
Media 
LBL-DR7 
LBL-DR7 
+ aLFA-1 
LBL-DR7 
+  ~I]:A-3 
Primary Stimulation 
i  i 
IL-2 
.dml) 
25  50 
[ 3H  J.171ymidine  Incolp. (cpm  xlO "3  ) 
Secondary  Stimulation 
I 
IL-2 
B  (pgtmt) 
Media  Primm7:I.BL-DR7  ] ~--] 
t-DR7/B7-1 
t-DRT/1CAM-t 
LBL-DR7 
25  5O 
I 
IL-2 
C  (pglmt) 
pritmor~: LBL-DR7 ] I---  ~ 
+ +u=.,.-..+  la4. 1 
25  50 
[ 3H].TT~ymldine  Incocp. (cpm  x10  "3) 
1670  Reversal  of Anergy by LFA-3 
Figure 7.  Anti-LFA-1 and anti-LFA-3 mAbs inhibit pri- 
mary response but do not result in induction of alloantigen- 
specific anergy. TC-1 cells were stimulated with LBL-DR7 
in the presence  of anti-LFA-1  or anti-LFA-3  mAb. IL-2 
accumulation and thymidine incorporation were measured 
as described in Fig. 1. After 72 h of primary culture, TC-1 
cells were isolated from LBL-DR7 by Ficoll separation, 
washed extensively,  and cultured in media without ILo2 
for 24 h. Each population was subsequently restimulated 
with a secondary stimulus as shown. Results are repre- 
sentative of two experiments. Table  1.  Stepwise  Induction and Reversal of Anergy 
Anergized 
after IL-2 
Anergized  after HLA- 
Untreated  Anergized  after IL-2  DK7/LFA-3 
TCK 
signaling  +  -  (?)*  +  + 
CD28 
signaling  +  -  (?)*  -  + 
IL-2 
secretion  +  -  +  + 
IL-2 receptor 
signaling  +  +  +  + 
CD2 
signaling  +  -  +  + 
* Since TC-1 cells do not respond to t-DK7/B7-1 or LBL-DK7, it is 
not possible to determine whether the defective signaling resides in the 
TCR or CD28 pathways. 
+, intact and  -, defective signaling. 
cells respond to alloantigen when costimulated via the CD28 
pathway and induce IL-2 secretion. Similarly,  they proliferate 
and secrete IL-2 when stimulated via the CD2 pathway with 
anti-T11.3  and either anti-T11.1 or anti-T11.2 mAbs. After 
alloantigen signaling via the TCR without B7 family costimu- 
lation, aUoreactive T cell clones are anergized. Anergized cells 
do not proliferate or secrete IL-2 in response to either alloan- 
tigen and costimulation by B7 family members or additional 
costimulatory molecules expressed on LBL-DR7. These results 
do not permit us to dissect whether the signaling defect in 
anergized cells resides in the TCR pathway, CD28 pathway, 
or both. Although anergized cells cannot secrete IL-2 in re- 
sponse to any stimuli,  the IL-2 receptor pathway is intact 
since these cells can proliferate in the presence of exogenous 
IL-2. Moreover, anergized cells cannot proliferate via the al- 
ternative CD2 pathway of T cell activation, and this lack of 
responsiveness appears to be associated with a downregula- 
tion of the functionally critical CD2K epitope. Taken together, 
these observations are consistent with the notion that anergy 
results in a combination of defective signaling via the TCR, 
CD28,  and  CD2 pathways. 
The reversal  of alloantigen-specific anergy requires both 
prolonged culture in IL-2 and simultaneous exposure to al- 
loantigen and LFA-3. The ability of previously anergized cells 
to respond to alloantigen and LFA-3 costimulation coincides 
temporally with the reappearance of CD2K and may depend 
on the ability of the anergized cells to reexpress CD2R. In 
contrast,  after culture in IL-2, anergized T  cells do not re- 
spond to t-DR.7/B7-1, demonstrating that CD28 costimu- 
lation is not involved in the reversal of anergy. These results 
are consistent with the hypothesis that reversal of anergy re- 
quires signaling via the IL-2 receptor pathway and reexpres- 
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sion of the critical CD2R epitope, followed by simultaneous 
activation via the TCR and CD2 pathways.  After reversal 
of anergy with IL-2, alloantigen,  and LFA-3, alloreactive T 
cells are again fully competent to respond to alloantigen and 
a variety of costimulatory  signals. 
Complete blockade of B7 family members with CTLA4-Ig 
appears  to  be  necessary  and  sufficient  to  induce  alloan- 
tigen-helper  T  cell-specific anergy  in  our  in  vitro model 
system. In contrast, partial blockade of B7-mediated costimu- 
lation with anti-B7-1 mAb resulted in reduced proliferation 
and IL-2 accumulation but did not result in unresponsive- 
ness on rechallenge.  These results are consistent with previous 
reports in both murine and human systems that demonstrated 
that CTLA4-Ig was more efficient than  anti-B7-1  mAb in 
the induction of alloantigen-specific anergy (21) and suggest 
that B7-2 costimulation can prevent the induction of anergy. 
Since LBL-DK7 cells express HLA-DR7 and many poten- 
tially important candidate costimulatory molecules,  our results 
demonstrate that all non-B7 family costimulatory molecules 
expressed on these cells  are not effective in preventing  the 
induction of anergy. The observed inhibition of LBL-DR7- 
mediated proliferation in primary culture by anti-LFA-1 and 
anti-LFA-3  mAbs is likely due to the disruption  of T  cell 
clone/APC  conjugate  formation  by  blockade  of LFA-1/ 
ICAM-1- and LFA-3/CD2-mediated adhesion. However, it 
is unclear why CD2 ligation by LFA-3 on the LBL-DR7 
cells is not capable to preventing  the induction  of anergy. 
Although anti-CD2 mAbs are capable of inducing modest 
levels  of IL-2  accumulation  in  TC-1  cells,  culture  with 
LBL-DR7 cells in the presence of CTLA4-Ig did not result 
in IL-2 accumulation (data not shown), suggesting that LFA-3 
on the cell surface may not be capable of inducing sufficient 
costimulation and IL-2 production to prevent the induction 
of anergy. 
The stepwise in vitro model described here should facili- 
tate the dissection of the biochemical and molecular events 
that  regulate  the  induction,  maintenance,  and  reversal  of 
anergy.  It should be possible now to determine more pre- 
cisely the defect(s) in the TCR, CD28, and CD2 pathways 
that are involved in the induction of anergy. Moreover, this 
model may provide a basis for design of novel therapeutic 
strategies to maintain or reverse the state of tolerance. Induc- 
tion and maintenance of a state of stable alloantigen-specific 
anergy will likely improve the results of transplantation  by 
decreasing the need for nonspecific immunosuppression. Our 
results  suggest  that  although  blockade of the  B7/CD28/ 
CTLA4 pathways may be useful to induce tolerance,  blockade 
of additional costimulatory pathways, which might reverse 
tolerance, will also be required.  In addition, our in vitro human 
model may provide insight into the mechanism(s) of autoim- 
munity.  Autoimmunity  might  result from reversal  of self- 
tolerance by microenvironmental  IL-2 and self-antigen pre- 
sentation  with  the  appropriate  costimulation.  Novel  ap- 
proaches to reverse active autoimmunity might be based on 
these data. Finally, anergy to tumor antigens might obstruct 
the development of important  T  cell-mediated  tumor im- 
mune  responses,  and  therefore  reversal  of  tumor  an- 
tigen-specific anergy might be essential to mount an efficient antitumor  immune  response.  Attempts  to  restore  tumor- 
specific immunity may need to be preceded by restoration 
of CD2 function in anergized T cells followed by rechallenge 
with tumor cells transfected with the essential costimulatory 
molecules. This study provides the rationale for preclinical 
murine  studies  to address  these hypotheses directly. 
We are grateful to Drs. Baruj Benacerraf,  Paul Anderson, Barbara Bierer, Eva Guinan, and David Hailer 
for discussions and critical review of this manuscript; and to Drs. Thomas Tedder for providing the anti- 
CD40 (JGR 12) mAb, Tim Springer for the anti-LFA-1  (TS1/22) and anti-LFA-3  (TS2/9) mAbs, Robert 
Karr for DR cDNAs,  and Brian Seed for LFA-3 cDNA.  We thank Laura  Saporito,  Herb Levine, and 
Gregory Bernstein for technical assistance.  L. M.  Nadler is a consultant to Repligen Corporation. 
This work was  supported by National Institutes of Health grants CA-34183  and CA-40416. 
Address correspondence to Dr. Vassiliki A. Boussiotis, Dana-Farber Cancer Institute, Dana 740, 44 Binney 
Street, Boston, MA 02115. 
Received for publication 26 April 1994 and in revised  form  12july  1994. 
References 
1.  Mueller, D.L., M.K. Jenkins, L. Chiodetti, and R.H. Schwartz. 
1990. An intracellular calcium increase and protein kinase C 
activation fail to initiate T cell proliferation in the absence of 
a costimulatory signal. J. Immunol. 144:3701. 
2.  van Seventer, G., Y. Shimizu, K. Horgan, and S. Shaw. 1990. 
The LFA-1 ligand ICAM-1 provides an important costimula- 
tory signal for T cell receptor-mediated activation of resting 
T  cells. J. Immunol. 144:4579. 
3.  Staunton, D.E., M.L. Dustin, and T.A. Springer.  1989. Func- 
tional cloning of ICAM-2,  a cell adhesion ligand for LFA-1 
homologous to ICAM-1. Nature fLorid.). 339:61. 
4.  Fougerolles, A.R., and T.A. Springer.  1992. Intercellular adhe- 
sion molecule 3, a third adhesion counter-receptor for lym- 
phocyte function-associated molecule 1 on resting lympho- 
cytes. J. Exp. Med. 175:185. 
5.  Moingeon, P., H.C. Chang, B.P. Wallner, Ch. Stebbins, A.Z. 
Frey, and E.L. Reinhertz. 1989. CD2-mediated adhesion facili- 
tates T lymphocyte antigen recognition function. Nature (Lond.). 
339:312. 
6.  Linsley, P.S., W. Brady, L. Grosmaire, A. Aruffo, N.K. Damle, 
and J.A. Ledbetter. 1991. Binding of the B cell activation an- 
tigen B7 to CD28 costimulates T cell proliferation and inter- 
leukin 2 mRNA  accumulation. J. Exp. Med. 173:721. 
7.  Gimmi, C.D.,  G.J.  Freeman, J.G. Gribben, K. Sugita, A.S. 
Freedman, C. Morimoto, and L.M. Nadler. 1991. B-cell sur- 
face antigen B7 provides a costimulatory signal that induces 
T cells to proliferate and secrete interleukin 2. Proc. Natl. Acad. 
Sci. USA.  88:6575. 
8.  Young, J.W.,  L.  Koulova, S.A.  Soergel, E.A.  Clark,  R.M. 
Steinman, and B. Dupont.  1992.  The B7/BB1 antigen pro- 
vides one of several costimulatory signals for the activation of 
CD4 + T lymphocytes by human blood dendritic cells in vitro. 
J.  Clin. Invest. 90:229. 
9.  Armitage, R.J., W.C. Fanslow, L. Strockbine, T.A. Sato, K.N. 
Clifford, B.M.  Macduff, D.M.  Anderson,  S.D.  Gimpel,  T. 
Davis-Smith,  C.R. Maliszewski et al. 1992. Molecular and bio- 
logical characterization of a murine ligand for CD40. Nature 
(Lond.). 357:80. 
10.  Liu, Y., B. Jones, A. Aruffo, K.M. Sullivan, P.S. Linsley, and 
C.A. Janeway, Jr. 1992. Heat-stable antigen is a costimulatory 
molecule for CD4 T  cell growth, j. Exp. Med. 175:437. 
11.  Schwartz, R.H. 1990. A cell culture model for T lymphocyte 
clonal anergy.  Science (Wash. DC). 248:1349. 
12. Jenkins, M.K., J.D. Ashwell,  and R.H. Schwartz. 1988. A1- 
logeneic non-T spleen cells restore the responsiveness of normal 
T cell clones stimulated with antigen and chemically modified 
antigen-presenting cells. J. Immunol. 140:3324. 
13. Jenkins, M.K., D.M. PardoU, J. Mizuguchi, T.M. Chused, and 
R.H.  Schwartz.  1987. Molecular events in the induction of 
a nonresponsive state in interleukin 2-producing helper T-lym- 
phocyte clones. Proc. Natl. Acad. Sci. USA.  84:5409. 
14.  Dallman,  M.J.,  O.  Shiho,  T.H. Page,  K.J.  Wood,  and P.J. 
Morris. 1991. Peripheral  tolerance to alloantigen results from 
altered regulation of the interleukin 2 pathway. J. Exp. Med. 
173:79. 
15.  Go, C., andJ. Miller. 1992. Differential induction of transcrip- 
tion factors that regulate the interleukin 2 gene during anergy 
induction and restimulation. J. Extx Med. 175:1327. 
16.  Kang, S.M., B. Beverly, A.C. Tran, K. Brorson, R.H. Schwartz, 
and M.J. Lenardo.  1992. Transactivation  of AP-1 is a molec- 
ular target ofT cell clonal anergy. Science  (Wash. IX?). 257:1134. 
17.  Harding, F.A., J.G. McArthur, J.A. Gross, D.H. Raulet, and 
J.P. Allison. 1992. CD28-mediated  signalling co-stimulates mu- 
rine T cells and prevents induction of anergy in T-cell clones. 
Nature (Lond.). 356:607. 
18.  Gimmi, C.D., G.J. Freeman,J.G. Gribben, G. Gray, and L.M. 
Nadler. 1993. Human T-cell clonal anergy is induced by an- 
tigen presentation in the absence of B7 costimulation. Proa 
Natl. Acad. Sci. USA.  90:6586. 
19.  Lenschow, D.J., Y. Zeng, J.R. Thistlethwaite, A. Montag, W. 
Brady, M.G. Gibson, P.S. Linsley, and J.A. Bluestone. 1992. 
Long-term survival of  xenogeneic pancreatic islet grafts induced 
by CTLA41g.  Science (Wash. DC). 257:789. 
20.  Turka, L.A., P.S. Linsley, H. Lin, W. Brady, J.M. Leiden, R.Q. 
Wei, M.L. Gibson, X.G. Zheng, S. Myrdal, D.  Gordon, et 
al., 1992. T-cell activation by the CD28 ligand B7 is required 
for cardiac allograft rejection in vivo. Proa Natl. Acad. Sci. USA. 
89:11102. 
1672  Reversal  of Anergy by LFA-3 21.  Tan, P., C. Anasetti, J.A. Hansen, J. Melrose,  M. Brunvard, 
J. Bradshaw, J.A. Ledbetter, and P.S. Linsley. 1993. Induction 
of alloantigen-specific hyporesponsiveness in human T  lym- 
phocytes by blocking interaction  of CD28 with its natural 
ligand B7/BB1. J. Exp.  Med.  177:165. 
22.  Lin,  H.,  S.F. Boiling,  P.S. Linsley,  R.-Q.  Wei,  D.  Gordon, 
C.B. Thompson, and L.A. Turka. 1993. Long-term acceptance 
of major histocompatibility complex mismatched cardiac  al- 
lografts induced by CTLA4Ig plus donor-specific transfusion. 
J. Exp.  Med.  178:1801. 
23.  Freedman, A.S., G.J. Freeman, J.C. Horowitz, J. Daley,  and 
L.M.  Nadler.  1987. B7,  a  B  cell  restricted  antigen  which 
identifies pre-activated B cells. J.  Immunol.  137:3260. 
24.  Freeman,  G.J.,  A.S.  Freedman,  J.M.  Segil,  G.  Lee,  J.F. 
Whitman, and L.M. Nadler. 1989. B7, a new member of the 
Ig superfamily with unique expression on activated and neo- 
plastic B cells. J.  Immunol.  143:2714. 
25.  Freedman, A.S.,  G.J. Freeman, K. Rhynhart, and L.M. Na- 
dler.  1991. Selective  induction  of B7/BBol  on interferon-3, 
stimulated monoeytes: a potential mechanism for amplification 
of T  cell  activation.  Cell Immunol.  137:429. 
26.  Symington, F.W., W. Brady,  and P.S. Linsley.  1993.  Expres- 
sion and function of B7 on human epidermal Langerhans cells. 
J. Immunol.  150:1286. 
27.  Augustin, M., A. Dietrich, R. Niedner, A. Kapp, E. Schopf, 
J.  Ledbetter,  W.  Brandy,  P.  Linsley,  and J.  Simon.  1993. 
Phorbol-12-myristate-13-acetate-treated human keratinocytes 
express B7olike molecules that  serve  a costimulatory role in 
T  cell  activation. J. Invest. Dermatol.  100:275. 
28.  Nickoloff,  B.,  R.  Mitra,  K.  Lee,  L.  Turka, J.  Green,  G. 
Thompson, and Y. Shimizu.  1993. Discordant expression of 
CD28 ligands, BB1, and B7 on keratinocytes  in vitro and psori- 
atic cells in vivo. Am. J. Pathol. 142:1029. 
29.  Boussiotis, V.A., G.J. Freeman, J.G. Gribben, J. Daley, G. Gray, 
and L.M. Nadler.  1993. Activated human B lymphoeytes ex- 
press three CTLA4 binding counter-receptors which costimu- 
late T  cell  activation. Proc. Natl.  Acad. Sci. USA.  90:11059. 
30.  Lenschow, D.J., G. Huei-Ting Su, L.A. Zuckerman, N. Nabavi, 
C.L. Jellis, G.S. Gray, J. Miller,  andJ.A. Bluestone. 1993. Ex- 
pression and functional significance of an additional ligand for 
CTLA-4. Proc. Natl. Acad. Sci. USA.  90:11054. 
31.  Hansen, J.A., P.J. Martin, and R.C. Nowinski. 1980. Mono- 
clonal antibody identifying a novel T-cell antigen and Ia an- 
tigen of human lymphocytes. Immunogenetics.  10:247. 
32.  Freeman, G.J., J.G. Gribben, V.A. Boussiotis, J.W. Ng, V. Res- 
tivo, L. Lombard, G.S. Gray, and L.M. Nadler. 1993. Cloning 
of B7-2: a CTLA4 counter-receptor that costimulates human 
T  cell proliferation. Science (Wash. DC).  262:909. 
33.  Freeman, G.J., F. Borriello,  R.J. Hodes, H. Reiser, K.S. Hath- 
cock, G. Laszlo, A.J. McKnight, J. Kim, L. Du, D.B. Lom- 
bard, et al. 1993. Uncovering the functional alternative CLTA4 
counter-receptor  in  B7-deficient  mice.  Science (Wash. DC). 
262:907. 
34.  Harper, K., C. Balzano, E. Rouvier, M.G. Mattei, M.F. Luo 
ciani, and P. Golstein. 1991. CTLA-4 and CD28 activated lym- 
phocyte molecules are closely related in both mouse and human 
as to sequence,  message expression, gene structure, and chro- 
mosomal location. J. Immunol.  147:1037. 
35.  Linsley, P.S., W. Brady, M. Urnes, L.S. Grosmaire, N.K. Damle, 
and J.A. Ledbetter. 1991. CTLA-4 is a second receptor for the 
B cell  activation antigen  B7. J. Exp.  Med.  174:561. 
36.  Boussiotis,  V.A., G.J. Freeman, G. Gray, J. Gribben, and L.M. 
Nadler.  1993.  B7 but  not intercellular adhesion molecule  1 
costimulation prevents the induction  of human alloantigen- 
specific tolerance. J.  Exp.  Med.  178:1753. 
37.  Beverly,  B.,  S.  Kang, M.  Lenardo,  and R.  Schwartz.  1992. 
Reversal of in vitro T cell clonal anergy by IL-2 stimulation. 
Int.  Immunol.  4:661. 
38.  Essery,  G., M.  Feldmann,  and J.  Lamp. 1988. Interleukin-2 
can prevent and reverse antigen-induced unresponsiveness in 
cloned human T  lymphocytes. Immunology.  64:413. 
39.  Goronzy, J., C. Weyland, and C.G. Fathhman. 1987. Cloning 
of human  alloreactive  T  cells. Methods Enzymol.  150:333. 
40.  Clark, E., and T. Yokochi. 1984. Human B cell and B cell blast- 
associated  surface  molecules defined with  monoclonal anti- 
bodies.  In  Leukocyte Typing.  A.  Bernard,  L.  Boumsell, J. 
Dausset,  C. Milstein,  and S.F. Sclossman, editors.  Springer- 
Verlang,  New York. 339. 
41.  Todd, R.I., S. Meuer, P. Romain, and S. Schlossman.  1984. 
A monoclonal antibody that blocks class II histocompatibility- 
related immune interactions.  Hum. Immunol.  10:23. 
42.  Rothlein, R., M. Dustin,  S. Martin,  and T. Springer.  1986. 
J. Immunol.  137:1270. 
43.  Sanchez-Madrid, F., A.M. Krensky, C. Ware, E. Robbins, J. 
Strominger, S. Burakoff, and T. Springer. 1982. Three distinct 
antigens associated  with human T  lymphocyte-mediated cy- 
tolysis: LFA-1, LFA-2, and LFA-3. Proc. Natl. Acad. Sci. USA. 
79:7489. 
44.  Abramson, C.S., J.H. Kersey, and T.W. Lebien. 1981. A mono- 
clonal antibody (BAol) reactive with cells of human B lym- 
phocyte lineage. J. Immunol.  126:83. 
45.  Dorken, B., A. Moller, A. Pezzutto, R. Schwartz-Albeiz, and 
G. Moldenhauer.  1989. B-cell antigens: CD72. In Leucocyte 
Typing IV. W. Knapp, B. Dorken, W.R.  Gilks, E.P. Rebier, 
R.E. Schmidt,  H. Stein, and A.E.G.Kr. von dem Borne, editors. 
Oxford University Press,  Oxford.  99. 
46.  Meuer, S., R. Hussey, M.  Fabbi,  D.  Fox, O. Acuto, K. Fit- 
gerald, J. Hodgdon, J. Protentis, S. Schlossmann, and E. Rein- 
herz. 1984. An alternative pathway of T-cell activation: a func- 
tional role for the 50kd Tll sheep erythrocyte receptor protein. 
Cell. 36:897. 
47.  Bierer, B., A. Peterson, J. Gorga, S. Herrmann, and S. Burakoff. 
1988. Synergistic T cell activation via the physiologic ligands 
for CD2  and the T  cell receptor. J. Exp.  Med.  168:1145. 
48.  Koyasu, S., T. Lawton, D. Novick, M.A. Recny, R.F. Siliciano, 
B.P. Wallner,  and E.L. Reinherz. 1990. Role of interaction of 
CD2 molecules with lymphocyte function-associated antigen 
3 in T-cell recognition of nominal antigen. Proc. Natl.  Acad. 
Sci.  USA.  87:2603. 
49.  Selvaraj, P., M.L. Plunkett, M. Dustin, M.E. Sanders, S. Shaw, 
and T.A. Springer.  1987. The T lymphocyte glycoprotein CD2 
binds the cell surface ligand LFA-3.  Nature (Lond.). 326:400. 
50.  Bierer, B., J. Barbarosa, S. Herrmann, and S.J. Bourakoff.  1988. 
Interaction of CD2 with its ligand,  LFA-3, in human T  cell 
proliferation. J.  Immunol.  140:3358. 
51.  Peterson,  A.,  and B.  Seed.  1987.  Monoclonal antibody and 
ligand binding sites of the T cell erythrocyte receptor (CD2). 
Nature  (Lond.). 329:842. 
52.  Yang,  S.Y., S.  Chouaib,  and  B.  Dupont.  1986.  A  common 
pathway for T lymphocyte activation involving both the CD3-Ti 
complex and CD2 sheep erythrocyte receptor determinants. 
J. Immunol.  137:1097. 
53.  Meuer, S.C. 1989. Tll cluster report: CD2. In Leucocyte Typing 
IV. W.  Knapp, B. Dorken,  W.R.  Gilks, E.P.  Rebier,  R.E. 
Schmidt, H. Stein, and A.E.G.Kr. von dem Borne, editors. Ox- 
ford University Press,  Oxford.  270. 
1673  Boussiotis  et al. 